Inovio Pharmaceuticals, Inc.

Company Snapshot: Inovio Pharmaceuticals, Inc.

Last Change Volume High Low

Company Overview

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative.

Featured Documents

Client News

  1. Aug 8 2017 Inovio Pharmaceuticals Reports 2017 Second Quarter Financial Results
  2. Jul 26 2017 Inovio Pharmaceuticals to Report Second Quarter 2017 Financial Results on August 8, 2017
  3. Jul 19 2017 Inovio Announces Pricing of Public Offering of Common Stock
  4. Jul 18 2017 Inovio Announces Proposed Public Offering of Common Stock